Navigation Links
OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
Date:11/6/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 6, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the completion of patient enrollment in the primary registration Phase 3 study, known as SYNERGY, evaluating custirsen in patients with advanced prostate cancer.

The SYNERGY study is designed to evaluate a survival benefit for custirsen, when added to first-line chemotherapy, in men with metastatic castrate-resistant prostate cancer (mCRPC). The SYNERGY study is the first of two, ongoing, pivotal Phase 3 studies evaluating a potential survival benefit for custirsen treatment in prostate cancer. 

Over 1000 men have been enrolled to the SYNERGY study, at 142 sites primarily in North America and Europe. The survival primary endpoint data are event-driven and results are expected by the end of 2013.

"Completing enrollment of SYNERGY is an exciting and important milestone for the custirsen development program and for our company," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "We are one step closer to our goal of truly understanding the clinical benefit of custirsen in a large, randomized Phase 3 study, and to bringing forward a new treatment that could potentially extend the lives of men with prostate cancer."

The SYNERGY trial was initiated based on results of the OncoGenex Phase 2 trial in patients with metastatic CRPC receiving custirsen in combination with first-line docetaxel chemotherapy. These patients experienced a 6.9 month improvement in overall survival in comparison with those patients who received docetaxel alone.

Custirsen has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel. The FDA has also agreed on the design of the SYNERGY trial through the special protocol assessment (SPA) p
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AMRI Announces Third Quarter 2012 Results
2. Egenix, Inc. Announces New Director
3. BioRestorative Therapies Announces Stock Trading On OTC Bulletin Board
4. WebMD Announces Third Quarter Financial Results
5. Life Technologies Announces Third Quarter 2012 Results
6. HealthTech Capital Announces Awards for the HealthTech Conference 2012 - Building a Business in the New HealthTech Ecosystem
7. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
8. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
9. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
10. Synthetic Biologics Announces $10.8 Million Financing
11. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... The World Molecular Imaging Society (WMIS) Board ... as Executive Director. Baird will assume leadership of ... WMIS vision is to encompass and promote preclinical and ... diseases in the developed and developing world. The ... by integrating the Academy of Molecular Imaging and the ...
(Date:5/17/2013)... Topricin Pain Relief and Healing ... listed among nationally recommended over-the-counter (OTC) health products ... "U.S. News" Health in collaboration with "Pharmacy Times." ... 1 Pharmacists Recommended designation” in the “Topical Analgesics” ... and is the only homeopathic formula to earn ...
(Date:5/17/2013)... occurs when the transplant recipient,s immune system identifies the ... was previously thought that T cells, the immune cells ... known as chemokines in order to migrate to the ... of Clinical Investigation , Fadi Lakkis and colleagues at ... chemokine stimulation of T cells is not required for ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The new ... Photonics21 at the association’s recent annual meeting drew ... EC Vice-President Neelie Kroes, who called the action “a ... and a stimulant to European innovation.” , The Board ... of the new Photonics PPP at its 29 April ...
Breaking Biology Technology:WMIS Appoints Lisa Baird as Next Executive Director 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3
... 7 Voler Systems ( http://www.volersystems.com ) has launched ... provides full-service consulting from concept and design to production ... are not deterring Voler from investing in key programs ... reducing time-to-market for new medical devices. During the economic ...
... Ltd. announced,today that the U.S. Food and Drug Administration ... MR-guided Focused Ultrasound,(MRgFUS) system for the treatment of women ... agency allows,physicians to treat up to 100% of the ... to half the fibroid tissue. , ...
... Enhanced Functionality Empowers Users to Take Full Control ... from Assessment to Results Disclosure - while Adhering ... Choose PharmaCM to Manage Their Clinical Trial Registration ... Intrasphere Technologies ( http://www.intrasphere.com ...
Cached Biology Technology:Voler Systems Continues Investments and Expands Services 2FDA Approves Label Change for Non-Invasive Fibroid Treatment 2FDA Approves Label Change for Non-Invasive Fibroid Treatment 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 2Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 4
(Date:5/16/2013)... developed at MIT may someday eliminate the need ... monitor their blood-sugar levels and inject themselves with ... glucose levels in the body and respond by ... the function of pancreatic islet cells, which are ... this type of system could ensure that blood-sugar ...
(Date:5/16/2013)... players and athletes choose to wear the color red ... in Psychological Science , a journal of the ... to do with their testosterone levels. , The new ... University of Sunderland and colleagues, demonstrated that males who ... had higher testosterone levels than other males who chose ...
(Date:5/16/2013)... years old give unprecedented insight into the evolutionary ... most species-rich groups among the modern bony fishes. ... from the Division of Paleontology and Geobiology at ... Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany have completed ... assign to the group of bony fishes that ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3High-testosterone competitors more likely to choose red 2Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... liposomes ?cell-like "water balloons" composed of artificially created ... revealed unexpected behavior in the presence of electrical ... science's understanding of biomembrane function in operating living ... and Michele Pysher have found that liposomes have ...
... have deadly consequences for humans and most animals but ... Cramp from The University of Queensland has found that ... periods of starvation, the green-striped burrowing frog is able ... months without food, than frogs that had eaten regularly. ...
... of all the genetic sequences in living organisms, has ... of the blueprint, unfortunately, has been unintelligible, with no ... to link genomic features to cell function. , A ... based non-profit research center, and Pacific Northwest National Laboratory ...
Cached Biology News:A frog's life is food for thought 2A frog's life is food for thought 3Fleshing out the genome 2
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... DNA Polymerase with a proprietary thermostable proofreading ... than standard Taq DNA polymerase, Double the ... DNA templates >20kb, Concentration: 5U/ul, Applications: high ... and mutagenesis We are part of Thermo ...
... The EnzChek Lysozyme Assay Kit (E-22013) ... measure levels of lysozyme,activity in solution. ... down to 20 U/mL (Figure 1). ... lysodeikticus cell,walls, which are labeled to ...
... based on measurenment of enzyme activity of ... microtiter plate. The procedure includes two incubation ... 2nd enzyme reaction) separated by a ... the determination of human enzymaticaly active TRAP ...
Biology Products: